<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625568</url>
  </required_header>
  <id_info>
    <org_study_id>VYNT-0126-001</org_study_id>
    <nct_id>NCT05625568</nct_id>
  </id_info>
  <brief_title>Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients</brief_title>
  <official_title>Phase 2, Double-Blind, Randomized, Placebo-Controlled Clinical Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Female Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyant Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vyant Bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, Phase 2, multicenter, double-blind, parallel-group,&#xD;
      placebo-controlled study to assess the safety, tolerability, and efficacy of oral treatment&#xD;
      with VYNT-0126 in female subjects 18-45 years of age with Rett syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, approximately 14 weeks</time_frame>
    <description>Incidence of adverse events (AEs), including serious adverse events (SAEs), will be compared across the two VYNT-0126 doses and placebo. SAEs and AEs will be examined throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Rett Syndrome Behavioral Questionnaire (RSBQ)</measure>
    <time_frame>Obtained at baseline, end of dose titration, and end of treatment (approximately 14 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the 24-Item Motor-Behavioral Assessment (MBA)</measure>
    <time_frame>Obtained at baseline, end of dose titration, and end of treatment (approximately 14 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Obtained at baseline, end of dose titration, and end of treatment (approximately 14 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I)</measure>
    <time_frame>Obtained at the end of dose titration and end of treatment (approximately 14 weeks).</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quantitative Electroencephalograms (EEGs)</measure>
    <time_frame>Obtained at baseline, end of dose titration, and end of treatment (approximately 14 weeks).</time_frame>
    <description>Quantitative EEGs will be explored as potential biomarkers of intervention effects on brain function and clinical severity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrophysiological Evoked Potentials</measure>
    <time_frame>Obtained at baseline, end of dose titration, and end of treatment (approximately 14 weeks).</time_frame>
    <description>Evoked potential following auditory and visual stimuli will be explored as potential biomarkers of intervention effects on brain function and clinical severity.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Rett Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg VYNT-0126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg VYNT-0126</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VYNT-0126</intervention_name>
    <description>Liquid for oral administration once daily</description>
    <arm_group_label>10 mg VYNT-0126</arm_group_label>
    <arm_group_label>5 mg VYNT-0126</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Liquid for oral administration once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females age 18-45 (inclusive)&#xD;
&#xD;
          -  Diagnosis of classic/typical Rett syndrome with a documented mutation of the MeCP2&#xD;
             gene&#xD;
&#xD;
          -  Severity rating of between 10 and 36 (Rett Syndrome Natural History/Clinical Severity&#xD;
             Scale)&#xD;
&#xD;
          -  Concomitant medications (including approved medications for treatment of Rett&#xD;
             syndrome) must be stable for &gt;4 weeks prior to enrollment&#xD;
&#xD;
          -  Able to receive liquid study drug orally or via gastrostomy tube (G-tube)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Actively undergoing neurological regression;&#xD;
&#xD;
          -  Abnormal QT interval, prolongation or significant cardiovascular history&#xD;
&#xD;
          -  Excluded concomitant medications&#xD;
&#xD;
          -  Current clinically significant (as determined by the investigator). cardiovascular,&#xD;
             endocrine, hepatic, renal, or respiratory disease&#xD;
&#xD;
          -  Gastrointestinal disease which may interfere with the absorption, distribution,&#xD;
             metabolism or excretion of the study medication&#xD;
&#xD;
          -  History of, or current cerebrovascular disease or brain trauma&#xD;
&#xD;
          -  History of, or current, malignancy&#xD;
&#xD;
          -  Clinically significant abnormalities in safety laboratory tests, vital signs, or ECG,&#xD;
             as measured at screening or baseline&#xD;
&#xD;
          -  Any condition which in the investigator's opinion would affect the ability of the&#xD;
             subject to participate in the study&#xD;
&#xD;
          -  Allergy to VYNT-0126 or any ingredients of the liquid formulation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rett Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

